Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Yuval Cohen Insider Profile
11 Followers
Yuval Cohen, CEO, Director at Corbus Pharmaceuticals, holds 84.40K shares in Corbus Pharmaceuticals (Ticker: CRBP).
Yuval Cohen Corbus Pharmaceuticals (CRBP)CEO, Director
Corbus Pharmaceuticals (CRBP)
CEO, Director
Ranked #2,179 out of 98,624 Corporate Insiders
Profitable Transactions
11 out of 28 Profitable Transactions
Average Return
+27.80%
Average return per transaction
Time Frame
Compare to
Insider Roles
CEO, Director
Roles that Yuval Cohen holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Nov 16, 2015 - Nov 16, 2016
Return:+358.80%
The most profitable trade made by Yuval Cohen
Yuval Cohen's Trading History
List of latest transactions for each holding click on a transaction to see Yuval Cohen's performance on stock
You May Also Like
Yuval Cohen insider profile FAQ
What is the percentage of profitable transactions made by Yuval Cohen?
The percentage of profitable transactions made by Yuval Cohen is 39%.
What is the average return per transaction made by Yuval Cohen?
The average return per transaction made by Yuval Cohen is 27.80%.
What stocks does Yuval Cohen hold?
Yuval Cohen holds: CRBP stocks.
What was Yuval Cohen’s latest transaction?
Yuval Cohen latest transaction was an Uninformative Buy of ―.
What was Yuval Cohen's most profitable transaction?
Yuval Cohen’s most profitable transaction was an Informative Buy of CRBP stock on November 16, 2015. The return on the trade was 358.80%.
What is Yuval Cohen's role in Corbus Pharmaceuticals?
Yuval Cohen's role in Corbus Pharmaceuticals is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.